Please continue to report adverse events to the FDA when patients develop them while taking any of these new and older drugs. Working together, we can all improve patient care.
You Might Also Like
Also By This Author
Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.
- Berkrot B. FDA declines to expand approval of Pfizer arthritis drug. Reuters. 2015 Oct 14.
- Pfizer Inc. News release: Pfizer receives complete response letter from FDA for oral XELJANZ (tofacitinib citrate) supplemental new drug application for moderate to severe chronic plaque psoriasis. 2015 Oct 14.
- Institute for Safe Medical Practices. Executive summary—two anti-TNF products post most injury reports. ISMP Quarter Watch. 2015 Sep 23.